International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Oncol Lett 2: [Related article:] 831–838, 2011; DOI: 10.3892/ol.2011.353
Subsequently to the publication of the above article, an interested reader drew to the authors' attention that, concerning the cellular invasion assay data shown in Fig. 3A on p. 835, data shown in the ‘LOCL-1 siRNA’ panel were strikingly similar to data that had already appeared in an article written by the same research group, which was published in the journal Oncogene.
After re-examining their original data, the authors were able to confirm that Fig. 3 had been assembled incorrectly in the above paper. A revised version of Fig. 3, now showing the correct data for the ‘LOCL-1 siRNA’ panel in Fig. 3A, is shown on the next page. Note that the revision made to this figure has not led to any significant changes in either the results or the conclusions reported in this paper. The authors are grateful to the Editor of Oncology Letters for allowing them this opportunity to publish a Corrigendum, and all the authors agree with its publication; furthermore, they apologize to the readership for any inconvenience caused.